About 1/3 of patients with ME from BRVO experience improvement in ME/Va without treatment by 3 months.
*1mg and 4mg triamcinolone were used (both showed same efficacy). The complications were higher in the 4mg triamcinolone group as compared to 1mg group, so 1mg is preferred.
*Ranibizumab was given as a monthly injection for first 6 months and then as PRN injection in the second 6 months (if Va < 20/40 or foveal thickness >250). Rescue grid laser was given at 3 and 9mo if certain criteria were met. Ranibizumab showed better efficacy at 6 months; it also demonstrated that its benefits from first 6 months monthly injections can be maintained in the second 6 months with a prn schedule treatment.
*Results for BRVO and CRVO were analyzed as a single group.
*Ranibizumab or sham injections were given monthly for 6 months; in the next 6 months, monthly ranibizumab PRN was allowed for all patients. Ranibizumab showed better efficacy at 6 months; it also showed better vision gains in as opposed to sham in delayed treatment group.
*Limitations: this was a retrospective study with lack of randomization.